Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a daily probiotic boost your immune defenses?

NCT ID NCT05632341

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a probiotic supplement called GCWB1176 in 100 adults with normal or slightly low white blood cell counts. Participants took either the supplement or a placebo daily for 8 weeks. Researchers measured changes in natural killer (NK) cell activity and other immune markers to see if the supplement could improve immune function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lactococcus lactis (a probiotic supplement)
What this could lead to
If it works, this could point toward a simple daily supplement to help support the immune system, potentially reducing the frequency of common colds or infections.
What could go wrong
This is a small, early-stage trial with only 100 participants, and results may not apply to everyone. The supplement may show no significant benefit over placebo, and individual results can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jan 2023

Finished

Mar 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. At the time of screening, 19 or 75 years 2. A person with a peripheral blood leukocyte level measured in Visit 1, 3x10\^3 cells/μl or more, 8x10\^3 cells/μl 3. Those who are more than one of the following standards * Those who had more than twice within one year of visiting 1 year. * {Common cold, acute tonsillitis, acute pharyngitis, acute laryngitis, acute rhinitis, etc. * Those who have stomatitis more than twice within 1 year of visit * Those who had Herpes Zoster infection within 1 year of visit 4. Those with a stress awareness scale (PSS) 16 or more 5. A person who agrees to participate in this human application test before the start of the human test and writes a written consent form Exclusion Criteria: 1. Those who are currently treating drugs due to underlying disease, etc. 2. Hypertension patients (systolic blood pressure 140 mmHg or higher or dichotomous blood pressure 90 mmHg or higher, human application test target 10 minutes stabilized) 3. Patients with diabetes with an fasting blood sugar at least 126 mg/dL or administering urine disease (oral blood sugar, insulin, etc.) 4. Those who are 0.1 UIU/mL or less, or 10 UIU/mL or more 5. Those who have vaccinated vaccines (influenza, corona, shingles that can affect immunity) within 3 months of visiting 1 6. A disease that can affect immune responses such as adult -like and rhinitis 7. AST (GOT) or ALT (GPT) is three times more than the normal upper limit of the embodiment 8. Those who are 1.5 times more than the normal upper limit of Creatinine 9. Those who administered steroids, antibiotics, immunosuppressants, and gastric acid inhibitors within 1 month of visit. 10. Visit 1 person who consumes vitamins, health functional foods that can affect immunity within 2 weeks of visiting 11. A person who has administered or consumed lactic acid bacteria products (4 or more times a week) within 2 weeks of visiting within 2 weeks of visit. 12. Those who complain of severe gastrointestinal symptoms such as heartburn and indigestion 13. Those who are pregnant or have a planning plan for lactation or this human application period 14. Those who have participated in other interventional clinical trials (including human application test) within 8 weeks of visit, or plan to participate in other interventional clinical trials (including human application tests) after the beginning of this human application test 15. Those who are sensitive or allergic to food ingredients for this human application 16. Those who have a BMI (body mass index) of 30 kg/m2 or more 17. A person who consumed alcohol within 1 month (30 days) based on 1 visit (man\> 210 g/week, woman\> 140 g/week) 18. Those who judge that the test person is inadequate for other reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immune function are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Seoul St. Mary's Hospital, College of Medicine

    Seoul, South Korea

  • St. Vincent's Hospital, College of Medicine

    Suwon, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.